Expert input on melasma treatment choices
Part of Skin clinical trials.
This study gathers expert dermatologists to create guidelines for managing melasma, a skin condition that causes dark patches. If you are an experienced dermatologist, your opinion could help shape future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a board-certified or equivalent dermatologist
- You have at least 5 years of experience treating melasma after your certification
- You are willing to participate in all rounds of the Delphi survey
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two injectable treatments for melasma (dark patches on the face): platelet-rich fibrin, which uses your own blood cells to promote healing, and tranexamic acid, a medication that may reduce pigmentation. The study will compare which works better for women with mild to moderate melasma.
This trial tests a microneedling technique combined with three topical medications (metformin, tranexamic acid, and a modified Kligman's formula) to treat melasma, a common skin condition causing dark patches. The goal is to see if this approach safely and effectively reduces melasma in eligible women.
This trial tests whether a cream containing metformin or tranexamic acid can reduce melasma (dark patches on the face). It aims to see which treatment works better.
This trial compares two treatments for melasma, a common skin condition causing dark patches on the face. One treatment uses an injection into the affected skin (tranexamic acid), while the other uses a chemical peel (mandelic acid). The study aims to see which works better and is safer for people with darker skin tones.
This study tests whether combining oral tranexamic acid with a special skin needling treatment helps reduce melasma (dark facial patches). It is designed for women aged 18-50 who have melasma and are not pregnant or on certain medications.
This trial tests two different triple-combination creams for melasma in women with skin types IV or V. Both creams contain a bleaching agent and a retinoid, but one uses a different steroid. The goal is to see which is safer and works better.
Hear when a new Melasma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.